An ATP-competitive dual Src/Abl kinase inhibitor (IC50 = 1 nM).1 It potently inhibits the apoptosis-linked STE20 kinases but does not inhibit Kit or PDGFR.2 Bosutinib was found to inhibit 16 of 18 imatinib-resistant mutant forms of Bcr-Abl expressed in m
* VAT and and shipping costs not included. Errors and price changes excepted